ARAY at a glance
ACCURAY INC (ARAY, SEC CIK 1138723) filed its latest 10-K annual report on August 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), ACCURAY INC (ARAY) reported revenue of $401.9 million (down 12.3% from FY2025) and a net loss of $49.2 million. Diluted EPS was -$0.40.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding ACCURAY INC (ARAY) shares worth $3.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $401.9M
- −12.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $3.8M · −4 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Business Overview
- Core business: Develops and sells robotic and helical radiation therapy systems with advanced software for precise cancer and tumor treatment
- New strategic 10-year collaboration with University of Wisconsin to advance personalized cancer treatments using Stellar adaptive radiotherapy platform
- Focus shift to expanding service offerings with AI-enabled remote diagnostics, workflow optimization, and predictive maintenance tools for recurring revenue growth
- Workforce size 809 employees as of June 30, 2026, with 392 employees outside the U.S., supporting global operations and expansion
- Notable regulatory progress: Received China NMPA approvals for Tomo C and Accuray Precision systems, enhancing market access in the significant China oncology market
Management Discussion & Analysis
- Net revenue $402M, down 12% YoY; product revenue declined 27% ($172.7M vs $237.6M), services revenue up slightly $8.3M
- Gross margin 27.7% vs 32.1% YoY; gross profit decreased $35.5M due to lower product sales, tariffs, and unfavorable product mix
- Best segment: EIMEA revenue $150.9M up 5%, worst: China $68.1M down 45% due to geopolitical, tariff challenges
- Operating expenses slightly down 1% to $137.9M; restructuring charges of $16.2M included; interest expense $32.9M up 154% due to new borrowings
- Cash flow from operations negative $7.0M; Capex $5.9M; financing cash inflows $7.0M mainly from credit facilities and tariff refund financing
- Management guiding for ongoing inflation, supply chain headwinds, and geopolitical risks to impact margins and cash flow through FY 2027
Risk Factors
- Regulatory risk: U.S. Supreme Court ruling on IEEPA tariffs invalidated broad tariff authority, impacting Section 301 tariffs on components (e.g., CyberKnife linac), causing $9.3M tariff refund claim delay
- Geopolitical/macroeconomic risk: $8.9M shipment delays in Middle East, North Africa, Pakistan due to regional geopolitical unrest and Chinese economic pressures, impacting service revenue in those regions
- Operational/supply chain risk: Single-source suppliers for critical CyberKnife and TomoTherapy components expose company to supply disruptions, inflationary cost increases, and manufacturing delays through at least fiscal 2027
- Competitive risk: Major competitors Varian, Elekta, and new entrants with superior or alternative cancer treatments risk obsolescence of CyberKnife and TomoTherapy platforms
- Financial risk: $182M term loan facility and $5M revolving credit facility with breached covenants and restrictive amendments require waivers; failure to comply risks asset foreclosure and going concern issues
AI summary of the ARAY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added financing risk: pending Series A transaction could require repayment of $15.0 million plus a $15.0 million fee if terminated
- Most materially updated trade risk: Section 301 tariffs affect CyberKnife linear accelerators manufactured in China and imported into the U.S.
- Regulatory risk: May 2026 voluntary CyberKnife recall involved collimator retention during exchange
- Near-term operational risk: Middle East disruption indefinitely delayed fiscal 2026 shipments and reduced regional service revenue
- Financial risk: Credit Facilities totaled $101.7 million net carrying value, all maturing June 6, 2030
Management Discussion & Analysis
- Revenue $86.5M, down 8% YoY from $93.9M, driven by lower product shipments
- Gross margin 30.1% vs 28.8% YoY, reflecting higher-margin service revenue mix
- Americas worst region: revenue $15.7M, down 37%; EIMEA strongest growth: $37.2M vs $34.3M
- Cash $42.3M; operating cash flow used $3.8M vs $12.2M provided YoY
- $15.0M investor proceeds; $4.9M software investment; outlook pressured by tariffs, supply chain costs through at least fiscal 2027
AI summary of the ARAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- Richard A. Meier elected Class II director through the 2029 annual meeting
- Executive compensation approved on an advisory basis, 33,332,520 for versus 5,793,203 against
Item 3.02: Unregistered Sales of Equity Securities
- Series A Preferred Stock issued in a private placement to Investors
- Transaction relied on Securities Act Section 4(a)(2) exemption, avoiding registered public offering requirements
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- 1-for-40 reverse split effective November 9, 2026, raising ARAY’s per-share trading price and reducing shares outstanding proportionally
- Nasdaq Capital Market trading continued under ARAY with new CUSIP 004397 303
Item 7.01: Regulation FD Disclosure
- Cancellation extinguished warrants covering approximately 27.6 million shares, removing substantial potential dilution
- Eliminated warrant exercise prices ranging from $1.25 to $1.68 per share
Item EX-99.1: Item EX-99.1
- TCW exchanged $40 million of term-loan principal for convertible preferred stock, materially reducing Accuray’s debt burden
- TCW’s $15 million cash investment converted into additional convertible preferred shares, providing balance-sheet capital
Item 3.03: Material Modification to Rights of Security Holders
- $55.0M Series A preferred issuance: $15.0M cash plus conversion of $40.0M existing investor debt
- 8% annual preferred dividend, compounding quarterly and payable in cash or added to stated value
Item 2.02: Results of Operations and Financial Condition
- Accuray reported fiscal 2027 first-quarter financial results for the period ended September 30, 2026
- Results announced November 4, 2026, with detailed figures and management commentary in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Investor presentation available from November 4, 2026, supporting ongoing analyst and investor communications
- Exhibit 99.2 contains the substantive company disclosures and should be reviewed for business outlook and investor-relevant updates
Item EX-99.1: Item EX-99.1
- Fiscal Q1 2027 revenue fell 8% to $86.5 million, driven by a 26% product decline to $27.3 million
- Service revenue grew 4% to $59.2 million, with service gross margin improving 120 basis points to 35.1%
AI summaries of ARAY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARAY
Don't miss the next ARAY filing
- Alerts as it files. A push when ARAY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARAY, by share count.
- Ask anything. An AI agent that reads every ARAY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| TCW GROUP INC | J | Nov 13, 2026 | 1,936 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 25,250 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 2,711 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 25,864 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 35,351 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 2,647 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 203,128 | - |
| TCW GROUP INC | J | Nov 13, 2026 | 36,210 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | $446.6M | $458.5M | $401.9M |
| Gross Profit | - | $147.0M | $111.5M |
| Operating Income | - | $7.8M | -$26.4M |
| Net Income | - | -$1.6M | -$49.2M |
| Gross Margin | - | 32.1% | 27.7% |
| Op. Margin | - | 1.7% | -6.6% |
| Net Margin | - | -0.3% | -12.2% |
| Balance Sheet | |||
| Total Assets | - | $470.2M | $443.7M |
| Equity | - | $81.2M | $41.7M |
| ROE | - | -2.0% | -118.0% |
| Per Share | |||
| EPS | - | $-0.02 | $-0.40 |
| Cash Flow | |||
| Operating CF | - | $2.9M | -$7.0M |
| CapEx | $3.6M | $4.3M | $5.9M |
Source: XBRL data in ACCURAY INC (ARAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ARAY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $3.8M |
| Q2 2026 | 22 | $4.8M |
| Q1 2026 | 26 | $9.2M |
| Q4 2025 | 25 | $22.1M |
| Q3 2025 | 25 | $44.3M |
| Q2 2025 | 25 | $35.5M |
| Q1 2025 | 24 | $30.0M |
| Q4 2024 | 19 | $30.3M |
- Fifth Third Bancorp+233 (+15%)
- AQR Capital Management−1.28M (-47%)
- BlackRock−703.3K (-22%)
- Goldman Sachs Group−474.6K (-59%)
- Millennium Management−84.4K (-5%)
- Renaissance Technologies LLC−75.0K (-4%)
- Citigroup+3.6K
- FMR LLC (Fidelity)−1.38M
- D.E. Shaw & Co−649.4K
- StoneX Group Inc.−33.1K
- Citadel Advisors LLC−31.6K
- Dimensional Fund Advisors−18.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARAY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 10-K | Aug 27, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| SC 13G | Jul 7, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - |
Related Health Care companies
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ARAY SEC filings: frequently asked questions
Which institutions hold ARAY stock?
As of September 30, 2026, the largest ACCURAY INC (ARAY) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.2 million), BlackRock ($692,000), Renaissance Technologies LLC ($538,000), Millennium Management ($406,000), AQR Capital Management ($387,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARAY's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), ACCURAY INC (ARAY) reported revenue of $401.9 million (down 12.3% from FY2025) and a net loss of $49.2 million. Diluted EPS was -$0.40. The figures come from the XBRL data in the 10-K.
What are the main risks in ARAY's latest 10-K?
In the 10-K filed August 27, 2026, ACCURAY INC (ARAY) flagged: Regulatory risk: U.S. Supreme Court ruling on IEEPA tariffs invalidated broad tariff authority, impacting Section 301 tariffs on components (e.g., CyberKnife linac), causing $9.3M tariff refund claim delay. Geopolitical/macroeconomic risk: $8.9M shipment delays in Middle East, North Africa, Pakistan due to regional geopolitical unrest and Chinese economic pressures, impacting service revenue in those regions. (AI summary of the Risk Factors section.)
What did ARAY report in its latest 8-K?
ACCURAY INC (ARAY) filed an 8-K on November 19, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Richard A. Meier elected Class II director through the 2029 annual meeting.
What are the latest ARAY SEC filings?
ACCURAY INC (ARAY) filed its latest 10-K annual report on August 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 17, 2026.
What is ARAY's SEC CIK number?
ACCURAY INC (ARAY)'s SEC Central Index Key (CIK) is 1138723. EDGAR lists every ARAY filing under that number.
Ask anything about ARAY
The research agent reads ARAY's filings, financials, insider trades and 13F holders, then answers with sources.